Curly....Joh,
I hear ya - but we are talking "pre-clinical" valuation....with data only from animals.
No human efficacy data yet.
However, I do agree if PAB do take the tech into the clinic and achieve good efficacy then the sky is the limitLike $15b to $20B TO type limit!
For now lets get to a realistic valuation comparable to NASDAQ peers.
.
PAB chart, page-1668
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $9.338K | 1.167M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103590 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 300000 | 1 |
View Market Depth
| Last trade - 15.05pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 266501 | ||
| Last updated 15.05pm 03/05/2024 ? | |||||
| PAB (ASX) Chart |